As regards the use of newer drugs, SGLT2 inhibitors have been shown to be potentially cost-effective in reducing diabetes complications in low- and middle-income countries [23], both in patients with established cardiovascular or renal disease and in newly diagnosed patients with type 2 diabetes without CVD [24]. This evidence concerns the gene SLC5A2 and kidney disorder.